(Q33337974)

25 July 2017

title

A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer (English)

1 reference

25 July 2017

main subject

metastatic breast cancer

1 reference

Miles DW

1

1 reference

25 July 2017

Smith IE

2

1 reference

25 July 2017

Coleman RE

3

1 reference

25 July 2017

Calvert AH

4

1 reference

25 July 2017

Lind MJ

5

1 reference

25 July 2017

publication date

1 July 2001

1 reference

European Journal of Cancer

25 July 2017

published in

1 reference

25 July 2017

volume

37

1 reference

25 July 2017

issue

11

1 reference

25 July 2017

page(s)

1366-1371

1 reference

A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900117-4

7 January 2021

Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900117-4

7 January 2021

Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900117-4

7 January 2021

Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900117-4

7 January 2021

Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900117-4

7 January 2021

A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900117-4

7 January 2021

Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900117-4

7 January 2021

Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900117-4

7 January 2021

Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900117-4

7 January 2021

Systematic reviews using individual patient data: a map for the minefields?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900117-4

7 January 2021

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900117-4

7 January 2021

Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900117-4

7 January 2021

Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900117-4

7 January 2021

Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900117-4

7 January 2021

Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900117-4

7 January 2021

Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900117-4

7 January 2021

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900117-4

7 January 2021

Low-dose oral fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900117-4

7 January 2021

A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900117-4

7 January 2021

10.1016/S0959-8049(01)00117-4

Identifiers

DOI

1 reference

25 July 2017

1 reference